Brief: Immune Therapeutics Today Announces Appointment Of Michael Handley As Its New Chief Executive Officer And Member Of The Board Of Directors
23/09/2019 14:33
Sept 23 (Reuters) - Immune Therapeutics Inc IMUN.PK :
* IMMUNE THERAPEUTICS TODAY ANNOUNCES APPOINTMENT OF MICHAEL
K.
HANDLEY AS ITS NEW CHIEF EXECUTIVE OFFICER AND MEMBER OF THE
BOARD OF DIRECTORS
* IMMUNE THERAPEUTICS INC - ANNOUNCES RESIGNATION OF ITS
FORMER
CEO, AND DIRECTOR, NOREEN GRIFFIN
* IMMUNE THERAPEUTICS INC - HANDLEY IS CURRENTLY CHIEF
EXECUTIVE
OFFICER AND CHAIRMAN AT ALETHEIA THERAPEUTICS CORP
Source text for Eikon: ID:nGNX9VF0lX
Further company coverage: IMUN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biostax
See all newsBrief: Biostax Corp Announces Voluntary Delisting From Otc Pink Market And SEC Deregistration
Brief: Biostax Corp. And Statera Biopharma Inc Reach Mutually Beneficial Dispute Settlement And Amended License Agreement Providing Clearer Clinical And Commercial Pathways For Both Companies
Brief: Immune Therapeutics Inc Announces Management Change
Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
Brief: Immune Therapeutics Today Announces Appointment Of Michael Handley As Its New Chief Executive Officer And Member Of The Board Of Directors